- Home
- MAC vs MRUS Comparison
MAC vs MRUS Comparison
Compare MAC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- MRUS
- Stock Information
- Founded
- MAC 1964
- MRUS 2003
- Country
- MAC United States
- MRUS Netherlands
- Employees
- MAC N/A
- MRUS N/A
- Industry
- MAC Real Estate Investment Trusts
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MAC Real Estate
- MRUS Health Care
- Exchange
- MAC Nasdaq
- MRUS Nasdaq
- Market Cap
- MAC 4.7B
- MRUS 5.1B
- IPO Year
- MAC 1994
- MRUS 2016
- Fundamental
- Price
- MAC $17.91
- MRUS $94.49
- Analyst Decision
- MAC Buy
- MRUS Buy
- Analyst Count
- MAC 12
- MRUS 18
- Target Price
- MAC $19.87
- MRUS $93.72
- AVG Volume (30 Days)
- MAC 2.2M
- MRUS 5.1M
- Earning Date
- MAC 11-04-2025
- MRUS 10-31-2025
- Dividend Yield
- MAC 3.89%
- MRUS N/A
- EPS Growth
- MAC N/A
- MRUS N/A
- EPS
- MAC N/A
- MRUS N/A
- Revenue
- MAC $1,049,150,000.00
- MRUS $56,228,000.00
- Revenue This Year
- MAC $12.09
- MRUS $47.25
- Revenue Next Year
- MAC $0.30
- MRUS N/A
- P/E Ratio
- MAC N/A
- MRUS N/A
- Revenue Growth
- MAC 32.06
- MRUS 59.77
- 52 Week Low
- MAC $12.48
- MRUS $33.19
- 52 Week High
- MAC $22.27
- MRUS $95.04
- Technical
- Relative Strength Index (RSI)
- MAC 56.37
- MRUS 80.98
- Support Level
- MAC $16.84
- MRUS $94.40
- Resistance Level
- MAC $17.45
- MRUS $95.02
- Average True Range (ATR)
- MAC 0.45
- MRUS 0.28
- MACD
- MAC 0.07
- MRUS -0.86
- Stochastic Oscillator
- MAC 79.72
- MRUS 37.21
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.1 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in March 2025.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.